<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253487</url>
  </required_header>
  <id_info>
    <org_study_id>CCHMC-04660</org_study_id>
    <secondary_id>CDR0000446082</secondary_id>
    <secondary_id>NCI-7036</secondary_id>
    <nct_id>NCT00253487</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas</brief_title>
  <official_title>A Pilot Study of Temozolomide and O-Benzylguanine for Treatment of High-Grade Glioma, Using Autologous Peripheral Blood Stem Cells Genetically Modified for Chemoprotection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as temozolomide, busulfan, and O6-benzylguanine,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells. O6-benzylguanine may also help temozolomide work better by making tumor&#xD;
      cells more sensitive to the drug. Radiation therapy uses high-energy x-rays to kill tumor&#xD;
      cells. Giving chemotherapy with a peripheral stem cell transplant or bone marrow transplant,&#xD;
      using stem cells from the patient that are genetically-modified in the laboratory to protect&#xD;
      them from the side effects of chemotherapy, may allow more chemotherapy to be given so that&#xD;
      more tumor cells are killed. Giving combination chemotherapy and radiation therapy together&#xD;
      with a peripheral stem cell transplant or bone marrow transplant may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving combination chemotherapy together&#xD;
      with radiation therapy works in treating younger patients who are undergoing an autologous&#xD;
      stem cell transplant for newly diagnosed gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and feasibility of a conditioning regimen comprising temozolomide,&#xD;
           radiotherapy, and busulfan followed by an infusion of autologous stem cells genetically&#xD;
           modified with the MGMT gene and temozolomide and O6-benzylguanine in younger patients&#xD;
           with newly diagnosed high-grade gliomas.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the tolerability of intrapatient dose escalation of temozolomide, in terms of&#xD;
           transgene expression, in patients treated with this regimen.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Surgery: Patients undergo biopsy or surgical debulking of the tumor. Two to six weeks&#xD;
           later, patients proceed to stem cell mobilization and apheresis.&#xD;
&#xD;
        -  Autologous stem cell mobilization and apheresis: Patients receive filgrastim (G-CSF)&#xD;
           subcutaneously or IV once daily for at least 4 days before apheresis and continuing&#xD;
           until apheresis is complete. Patients undergo apheresis for up to 4 consecutive days&#xD;
           until a target number of 5 X 10^6 CD34-positive peripheral blood stem cells (PBSCs) are&#xD;
           collected. Patients with insufficient numbers of PBSCs either undergo bone marrow&#xD;
           harvest to collect a sufficient number of cells or are removed from the study. The cells&#xD;
           are selected for CD34-positive cells which are cryopreserved for later use. Patients&#xD;
           then proceed to chemoradiotherapy.&#xD;
&#xD;
        -  Chemoradiotherapy: Patients receive oral temozolomide once daily on days 1-42 and&#xD;
           undergo radiotherapy once daily, 5 days a week, for 6 weeks. Four to eight weeks later,&#xD;
           patients proceed to the low-intensity, nonmyeloablative conditioning regimen.&#xD;
&#xD;
        -  Autologous PBSC or bone marrow transduction: Peripheral blood or bone marrow&#xD;
           CD34-positive stem cells are transduced with the MGMT gene on day -4.&#xD;
&#xD;
        -  Low-intensity, nonmyeloablative conditioning regimen: Patients receive busulfan IV over&#xD;
           2 hours on days -3 and -2. Patients then proceed to autologous PBSC or bone marrow&#xD;
           infusion.&#xD;
&#xD;
        -  Autologous PBSC or bone marrow infusion: Patients undergo autologous stem cell infusion&#xD;
           using transduced PBSCs or bone marrow on day 0. Three to six weeks later, patients&#xD;
           proceed to chemotherapy.&#xD;
&#xD;
        -  Chemotherapy: Patients receive O6-benzylguanine IV over 1 hour followed by oral&#xD;
           temozolomide once daily on days 1-5. Treatment repeats every 4 weeks for up to 6 courses&#xD;
           in the absence of disease progression or unacceptable toxicity. Patients experiencing&#xD;
           unacceptable toxicity due to O6-benzylguanine may receive temozolomide alone. Patients&#xD;
           not experiencing dose-limiting toxicity and who have at least 5% transduced neutrophils&#xD;
           by peripheral blood analysis after course 1 receive escalating doses (intrapatient) of&#xD;
           temozolomide during courses 2-6. Some patients undergo second-look surgery after the&#xD;
           first course of chemotherapy.&#xD;
&#xD;
      After completion of study therapy, patients are followed monthly for 3 months, every 3 months&#xD;
      for 3 years, every 6 months for 4 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-benzylguanine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed high-grade glioma of 1 of the following&#xD;
             types:&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
                    -  WHO grade IV disease&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
                    -  WHO grade III disease&#xD;
&#xD;
          -  No low-grade disease (i.e., WHO grade I-II disease)&#xD;
&#xD;
          -  No WHO grade III oligodendroglioma or oligoastrocytoma&#xD;
&#xD;
          -  Patients &gt; 30 years of age who have undergone a gross total resection and have&#xD;
             nonmeasurable disease as seen on postoperative MRI are eligible&#xD;
&#xD;
          -  Measurable disease, as assessed by postoperative MRI, is required in patients ≤ 30&#xD;
             years of age&#xD;
&#xD;
          -  No tumor arising in the spine or brainstem&#xD;
&#xD;
          -  No metastatic disease in the spine&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  5 to 55&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 50-100% (for patients 11-30 years of age) OR&#xD;
&#xD;
          -  Lansky 50-100% (for patients 5-10 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 9 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3 (transfusion independent)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Albumin ≥ 2.0 g/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen and core antibody negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 70 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Neurologic deficits must be stable or decreasing&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided dose is stable or decreasing&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars M. Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <verification_date>January 2006</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>January 3, 2014</last_update_submitted>
  <last_update_submitted_qc>January 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2014</last_update_posted>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

